GlaxoSmithKline is under investigation by the United Kingdom’s Serious Fraud Office. The drugmaker announced the investigation Tuesday and said in a statement that it is “committed to operating its business to the highest ethical standards,” and will cooperate with the government investigation.
The New York Times reported that neither GSK nor the UK agency would discuss just what is being investigated, but noted the string of allegations of misconduct by authorities in China, the most recent one being accusations that GSK employee Mark Reilly implemented a bribery scheme in China.
The company has also been accused of misconduct in Iraq, Jordan and Lebanon, among other locations.
